Silence Therapeutics Plc - American Depository Share (SLN)
SLN moved a median of +0.06% 30 minutes after news, and +0.45% by the close. How SLN actually reacts to news — the realized, point-in-time move the market made, measured across 261 labeled events over the last three years with zero look-ahead.
SLN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 247 |
| 30-min | +0.06% | 52% | 261 |
| 60-min | +0.04% | 50% | 261 |
| to close | +0.45% | 52% | 255 |
| Middle 50% of SLN reactions | -1.60% to +1.87% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 261 |
Half of all Silence Therapeutics Plc - American Depository Share news events land between -1.60% and +1.87% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SLN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | +5.22% | 73% | +10.61% |
| Rating reiterations | 72 | +0.02% | 50% | -0.75% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how SLN ranks against every other measured name →
That’s how SLN usually reacts — get an email when it moves on news →Email me when SLN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SLN's baseline. Nothing else.
Recent SLN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Silence Therapeutics plc (Nasdaq – SLN), Option Care Health, Inc. (Nasdaq – OPCH), RXO Inc. (NYSE – RXO), Sangoma Technologies Corporation (Nasdaq – SANG) | Press release | GlobeNewswire | +0.05% | +0.20% | |
| Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset | Press release | Business Wire | +0.03% | +0.00% | |
| Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany | Press release | Business Wire | +0.03% | +0.00% | |
| SLN Stock Alert: Halper Sadeh LLC is Investigating Whether Silence Therapeutics plc is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.00% | -0.08% | |
| Form 8-K Southland Holdings, Inc. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | +0.51% | |
| Silence Therapeutics to Participate in Three September Investor Conferences | Press release | Business Wire | +1.36% | +0.61% | |
| Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs | Press release | Business Wire | +0.73% | +4.36% | |
| Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering | Press release | Business Wire | +1.97% | -7.93% | |
| Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile | Press release | Business Wire | -3.64% | — | |
| Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results | Press release | Business Wire | -3.64% | — | |
| Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera | Press release | Business Wire | -3.64% | — | |
| Form 8-K/A Silence Therapeutics For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -0.51% | -2.87% | |
| Form 8-K Silence Therapeutics For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +20.68% | |
| Form 8-K Silence Therapeutics For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | +1.78% | +0.45% | |
| Form 8-K Silence Therapeutics For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +1.74% | +10.41% | |
| Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera | Press release | Business Wire | +1.74% | +10.41% | |
| Form EFFECT Silence Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -2.55% | +2.85% | |
| Silence Therapeutics to Participate in Jefferies Global Healthcare Conference | Press release | Business Wire | -0.74% | +1.34% | |
| Form 8-K Silence Therapeutics For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -4.47% | |
| Form S-3 Silence Therapeutics | SEC filing · Form S-3 | SEC EDGAR | -3.48% | -4.47% | |
| Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference | Press release | Business Wire | -0.42% | -5.30% | |
| Form 10-Q Silence Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.44% | -4.40% | |
| Form 8-K Silence Therapeutics For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -4.40% | |
| Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results | Press release | Business Wire | -1.44% | -4.40% | |
| Form ARS Silence Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.12% | +1.95% | |
| Form DEF 14A Silence Therapeutics For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | +1.12% | +1.95% | |
| Form 10-K Silence Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.96% | +1.85% | |
| Form 8-K Silence Therapeutics For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -2.96% | +1.85% | |
| Form S-8 Silence Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.00% | — | |
| Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | -2.96% | +1.85% | |
| Form 8-K Southland Holdings, Inc. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | +3.67% | |
| Form 8-K Southland Holdings, Inc. For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -1.90% | |
| Form 8-K Southland Holdings, Inc. For: Jan 16 | SEC filing · Form 8-K | SEC EDGAR | -1.19% | +3.38% | |
| Form 8-K Southland Holdings, Inc. For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -0.65% | |
| Form 8-K Southland Holdings, Inc. For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | -1.12% | -1.76% | |
| Form 8-K Silence Therapeutics For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | +2.54% | |
| Form 8-K/A Silence Therapeutics For: Dec 14 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | -2.34% | |
| TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth | Press release | Business Wire | +0.77% | -4.13% | |
| Form 8-K Silence Therapeutics For: Dec 14 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -4.13% | |
| Silence Therapeutics Announces Leadership Changes | Press release | Business Wire | -1.43% | +4.76% | |
| Form 10-Q Southland Holdings, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | — | |
| Form 8-K Southland Holdings, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | — | |
| Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | Press release | Business Wire | -1.04% | +0.30% | |
| Form 10-Q Silence Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.84% | +3.20% | |
| Form 8-K Silence Therapeutics For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -3.84% | +3.20% | |
| Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | Business Wire | -3.84% | +3.20% | |
| Form 8-K Silence Therapeutics For: Oct 23 | SEC filing · Form 8-K | SEC EDGAR | -1.50% | +1.54% | |
| Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) | Press release | Business Wire | -1.50% | +1.54% | |
| Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight | Press release | PR Newswire | +1.15% | +0.38% | |
| Silence Therapeutics to Participate in September Investor Conferences | Press release | Business Wire | +2.96% | -2.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SLN section they belong to.
Where else SLN is measured.
SLN earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Silence Therapeutics Plc - American Depository Share's median reaction calculated?
Every labeled SLN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 261 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of SLN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SLN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.